Alpha-1 Antitrypsin Deficiency: Beyond augmentation, a new path

Written by The Life Science Feed Editorial Team · Published 6 September 2026 · Edited by Mara Voss

Alpha-1 Antitrypsin Deficiency (AATD) presents a chronic, progressive genetic disorder primarily affecting the lungs and liver. The core pathology stems from insufficient functional alpha-1 antitrypsin (AAT) protein, leading to unchecked elastase activity and subsequent tissue damage. Current management strategies aim to mitigate disease progression, but the field continues to seek therapies that not only restore AAT levels but also demonstrate tangible clinical benefits for patients.

KEY TAKEAWAYS

- The Pivot: New therapeutic approaches for AATD are moving beyond simple protein replacement to focus on restoring endogenous AAT production or function.
- The Data: While specific trial data is not available, the goal for these emerging therapies is to achieve sustained normalization of AAT levels, ideally within the protective range of >11 µM.
- The Action: Clinicians should monitor the evolving landscape of AATD treatments, particularly those targeting genetic correction or enhanced endogenous protein production, for their potential to alter long-term disease trajectories.

Alpha-1 Antitrypsin Deficiency is an inherited disorder characterized by low circulating levels of alpha-1 antitrypsin, a serine protease inhibitor (SERPIN) primarily synthesized in the liver. This deficiency results from mutations in the SERPINA1 gene, with the most common severe variant being the PiZZ genotype. The primary physiological role of AAT is to protect tissues, particularly the lungs, from proteolytic degradation by neutrophil elastase. Without adequate AAT, elastase activity goes unchecked, leading to progressive destruction of alveolar walls and the development of emphysema, often indistinguishable from smoking-induced COPD but occurring at an earlier age and in non-smokers. Liver disease, including cirrhosis and hepatocellular carcinoma, also manifests in a subset of patients due to the accumulation of misfolded AAT protein within hepatocytes.

The current standard of care for individuals with severe AATD-related lung disease is weekly intravenous augmentation therapy, which involves infusing purified human plasma-derived AAT. This therapy aims to increase serum AAT levels above a putative protective threshold, typically defined as 11 µM (or 80 mg/dL), thereby restoring the antiprotease shield in the lungs. Augmentation therapy has been shown to slow the decline in lung function, particularly forced expiratory volume in one second (FEV1), and reduce the frequency of exacerbations in some patient populations. But it is a lifelong commitment, requires frequent intravenous access, and does not address the underlying genetic defect or the hepatic manifestations of the disease. The need for more convenient, effective, and disease-modifying treatments remains substantial, driving research into novel therapeutic modalities.

Understanding the Pathophysiology and Unmet Needs

The pathophysiology of AATD is dual-pronged. In the lungs, the deficiency of functional AAT leads to an imbalance between proteases and antiproteases, favoring proteolytic breakdown. Neutrophil elastase, released during inflammation, is a key culprit, degrading elastin and other extracellular matrix components. This process is exacerbated by environmental factors like smoking and recurrent respiratory infections. The resulting damage manifests as panacinar emphysema, predominantly affecting the lung bases. For patients with severe lung disease, the progressive loss of lung function significantly impacts quality of life, exercise capacity, and overall survival. The diagnosis and management of interstitial lung diseases, including AATD-related emphysema, often requires a multidisciplinary approach.

In the liver, the most common PiZZ mutation leads to the production of a misfolded AAT protein that polymerizes and accumulates within the endoplasmic reticulum of hepatocytes. This accumulation triggers cellular stress, inflammation, and apoptosis, which can progress to fibrosis, cirrhosis, and an increased risk of hepatocellular carcinoma. Not all individuals with the PiZZ genotype develop significant liver disease, indicating a complex relationship of genetic and environmental modifiers. Augmentation therapy does not address the hepatic polymerization and accumulation of AAT, leaving a significant unmet need for therapies that can prevent or reverse liver damage. The current treatment paradigm for liver involvement is largely supportive, with liver transplantation being the only definitive treatment for end-stage liver disease.

Emerging Therapeutic Strategies

The field is exploring several innovative strategies to overcome the limitations of current augmentation therapy. These approaches can be broadly categorized into those aiming to increase functional AAT levels, those targeting the misfolded protein in the liver, and those focused on gene correction. One avenue involves enhancing endogenous AAT production or secretion. Small molecule chaperones are being investigated to improve the folding and secretion of the mutant

AAT protein from hepatocytes, potentially increasing circulating AAT levels and reducing hepatic accumulation. This approach could offer a dual benefit, addressing both lung and liver manifestations of the disease. Another strategy involves RNA interference (RNAi) to reduce the production of the mutant AAT protein in the liver, thereby preventing its accumulation and associated liver damage. This would not increase circulating AAT levels, so it would likely require concomitant augmentation therapy for lung protection, but it could be transformative for liver disease.

Gene therapy represents a more fundamental approach, aiming to introduce a functional copy of the SERPINA1 gene into cells, typically hepatocytes, to enable sustained production of normal AAT protein. Viral vectors, such as adeno-associated viruses (AAV), are being explored for this purpose. The goal is to achieve stable, therapeutic levels of AAT in the bloodstream, potentially eliminating the need for lifelong augmentation therapy. This is a complex undertaking, given the challenges of sustained gene expression, immune responses to viral vectors, and ensuring adequate AAT distribution to the lungs. But the potential for a one-time or infrequent treatment that addresses the root cause of the deficiency is highly appealing. The aim for AAT restoration and clinically meaningful endpoints is a central theme across all these investigational therapies.

Defining Clinically Meaningful Endpoints

For any new AATD therapy to gain widespread adoption, it must demonstrate not only biochemical efficacy (i.e., increased AAT levels or reduced hepatic burden) but also clinically meaningful benefits for patients. In lung disease, traditional endpoints include the rate of decline in FEV1, exacerbation frequency, and quality of life measures. FEV1 decline, while a standard measure, can be slow and variable, requiring long and large trials to demonstrate a statistically significant effect. Exacerbation rates are more immediate but can also be influenced by many factors. Imaging biomarkers, such as CT densitometry to quantify emphysema progression, are increasingly being used as objective measures of lung destruction and may serve as surrogate endpoints or provide earlier signals of efficacy. For a comprehensive overview of respiratory conditions, the Oxford Handbook of Respiratory Medicine is an invaluable resource.

In liver disease, clinically meaningful endpoints include the prevention or reversal of fibrosis, reduction in liver stiffness (measured by transient elastography), and ultimately, prevention of cirrhosis and hepatocellular carcinoma. Liver biopsy remains the gold standard for assessing fibrosis, but non-invasive markers are preferred for their practicality and lower risk. Reductions in liver enzyme levels or markers of liver injury can also provide early indications of therapeutic effect. The challenge lies in demonstrating long-term benefits in a disease that progresses slowly and heterogeneously. The open-label design of some early-phase studies is an obvious caveat, as it introduces potential for bias, particularly in subjective endpoints. The trial populations are often small, limiting the generalizability of findings to the broader AATD population, which includes a spectrum of genotypes and disease severities. Whether benefits extend to patients with established cirrhosis or advanced emphysema remains unclear in many early-stage investigations.

Patient-reported outcomes (PROs) are also gaining prominence as endpoints that reflect the impact of the disease and its treatment on a patient's daily life. Measures of dyspnea, fatigue, exercise tolerance, and overall well-being provide a holistic view of treatment benefit. Regulators increasingly emphasize the importance of PROs alongside objective clinical and biochemical markers. The development of new therapies for AATD must consider the entire patient experience, not just laboratory values. The field is also grappling with the heterogeneity of AATD, where different genotypes and varying degrees of environmental exposure lead to diverse clinical presentations. A therapy that works well for a PiZZ individual

with severe lung disease might not be appropriate or effective for a patient with moderate liver involvement and minimal lung symptoms. This complexity necessitates careful patient selection and stratified trial designs.

The cost-effectiveness of novel therapies is another critical consideration. Augmentation therapy is already expensive, and any new treatment must demonstrate a favorable benefit-risk profile and economic value to be accessible to patients. This includes not only the direct costs of the therapy but also the potential for reduced hospitalizations, improved productivity, and enhanced quality of life. The long-term safety profiles of gene therapies and RNAi-based treatments are also paramount, given their potential for durable effects and the need to avoid unforeseen off-target effects. The scientific community continues to refine methodologies for assessing these complex endpoints, aiming for data from a sufficient number of patients (n) and with a clear confidence interval (CI) that can inform clinical practice and regulatory decisions. The ongoing research into patient and pulmonologist perspectives on IPF/PPF highlights the importance of understanding the lived experience of chronic lung disease, a lesson directly applicable to AATD.

CLINICAL IMPLICATIONS

The shift in AATD research from simple protein replacement to more targeted, disease-modifying strategies marks a significant evolution. Clinicians should recognize that while augmentation therapy remains the cornerstone for lung disease, it is not a complete solution, particularly for hepatic manifestations. The emergence of therapies that aim to correct the underlying genetic defect or prevent misfolded protein accumulation could fundamentally alter the disease trajectory.

For patients, these advancements offer the prospect of less burdensome treatment regimens and, potentially, a halt or reversal of disease progression in both the lungs and liver. The focus on clinically meaningful endpoints, including patient-reported outcomes, is a welcome development, ensuring that new treatments deliver tangible benefits beyond just biochemical markers. This holistic view is essential for improving quality of life.

But the journey from research showing early positive results to approved therapy is long and fraught with challenges. The heterogeneity of AATD, the slow progression of the disease, and the need for long-term safety data mean that definitive answers will take time. The economic implications of potentially curative or highly effective therapies will also need careful consideration, ensuring equitable access for all eligible patients.

The field is moving towards a future where AATD management is more personalized and effective. GPs and specialists alike will need to stay abreast of these developments, understanding the nuances of each new therapeutic class and its potential role in managing this complex genetic disorder. The goal is not just to raise AAT levels, but to truly improve patient lives.

REFERENCES

1. 1. Dasí F. Alpha-1 antitrypsin deficiency. Med Clin (Barc). 2024;162(7):336-342. doi:10.1016/j.medcli.2023.10.014

2.

2. Strnad P, McElvaney NG, Lomas DA. Alpha(1)-Antitrypsin Deficiency. N Engl J Med. 2020;382(15):1443-1455. doi:10.1056/NEJMra1910234

3. 3. de Vos JD, Hillberg O, Perch M, Jensen JU, Wilcke JT, Løkke A. [Alpha-1-antitrypsin deficiency]. Ugeskr Laeger. 2021;183(30). PMID:34356027

4. 4. Mornex JF. [Alpha 1-antitrypsin deficiency]. Rev Mal Respir. 2022;39(8):698-707. doi:10.1016/j.rmr.2022.02.062

5. 5. Fähndrich S, Bals R. [Alpha 1-antitrypsin deficiency]. Inn Med (Heidelb). 2024;65(6):533-537. doi:10.1007/s00108-024-01722-2

6. 6. Perlmutter DH. Alpha-1-antitrypsin deficiency. Semin Liver Dis. 1998;18(3):217-25. doi:10.1055/s-2007-1007158